tradingkey.logo

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

ReutersJun 4, 2025 11:16 AM

Corvus Pharmaceuticals Inc CRVS.O:

  • CORVUS PHARMACEUTICALS ANNOUNCES FULL DATA FROM COHORT 3 OF PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS

  • CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS CLINICALLY MEANINGFUL REDUCTION IN ITCH BY DAY 8

  • CORVUS PHARMACEUTICALS INC - ALL COHORTS SHOW STATISTICALLY SIGNIFICANT DIFFERENCE FROM PLACEBO AT DAY 28

  • CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS EARLIER AND DEEPER RESPONSES COMPARED TO COHORTS 1-2

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI